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VHH are polypeptides (15 kDa) derived from the variable
domain of single heavy-chain antibodies of Camelidae.
They represent the smallest antigen-binding fragment of
an antibody (human IgG = 150 kDA). VHH are currently
being explored for a number of applications.
Anti-rabies virus VHH were cloned from lymphocytes
of vaccinated llamas and selected for their affinity with
the viral spike glycoprotein G and neutralizing potency
in a cellular infection assay. Linkage of two VHH
allowed recognition of two identical or different epitopes
and increased the neutralizing potency in cells more
than a hundred-fold. Next, we examined the protection
efficiency of these bimeric VHH in vivo.
Contrary to irrelevant control VHH, pre-incubation
of the virus with anti-G VHH fully protected mice
against disease and mortality upon inoculation of the
virus-VHH mix in the nose, muscle or brain. Preven-
tive administration of anti-G VHH in the nose, 24
hours prior to intranasal virus challenge, also almost
completely prevented disease and lethal infection. This
suggests that VHH remain sufficiently active for at
least 24 hours at the site of administration in the nose
to neutralize a significant part of the invading virus.
Post exposure prophylaxis (PEP) by injection of anti-G
VHH in the left quadriceps muscle 10 minutes after
virus challenge in the right quadriceps muscle reduced
mortality by 50%. Treatment 24 hours after virus chal-
lenge was however no longer effective, most likely
because the virus had already reached the central ner-
vous system and was no longer exposed to locally
administered VHH.
Our results show that anti-G VHH can neutralize
rabies virus in an Fc-independent way. VHH probably
hinder the recognition of cellular receptors or interfere
with the fusion of viral and cellular membranes. The
bimeric constructs proved protective in different chal-
lenge models, but that protection in the PEP model was
weak. This might be due to the short half-life of the
used VHH. Considering that prolongation of the half-
life of VHH is feasible by different approaches, VHH
technology may offer perspectives as an alternative to
antibodies for PEP. VHH have a low production cost,
not contaminated by blood-borne pathogenic agents and
are less likely to evoke allergic or immunopathological
reactions. They have good thermal stability, which is an
advantage in developing countries, where the cold chain
for distribution and preservation can not always be
guaranteed.
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